The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | PROTON-PANC: proton therapy in adjuvant pancreatic cancer
Benjamin Adam Weinberg, MD, Georgetown University, Washington, DC, describes the trial design and rationale of the Phase I PROTON-PANC trial (NCT03885284), which assessed proton radiation therapy in patients with pancreatic adenocarcinoma (PAC). 5 fractions of proton radiation therapy (PRT) were administered between cycles of adjuvant modified FOLFIRINOX. The radiation will aim to target local recurrence, which can negatively impact survival in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
